This site was built to comply to Web authoring standards, and is best viewed in a standards-compliant browser. You may download one free from Netscape or Microsoft. You do not need to download a new browser, however, to have complete access to all information in this site.

July 05, 2008 (updated 7/3/2008)
Home | Contact Us | Glossary | Site Map | Legal Notices
COMPANYTECHNOLOGYNEUMUNEPROGRAMSNEWS ROOMINVESTORSCAREERS Hollis-Eden

PRESS RELEASES

June 09, 2008

Hollis-Eden Pharmaceuticals Reports Additional Positive Data from Phase I/II Clinical Trial with TRIOLEX(TM) Supporting Anti-Inflammatory Approach to Treating Type 2 Diabetes >>

May 13, 2008

Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Programs; Announces First Quarter 2008 Financial Results >>

May 12, 2008

Hollis-Eden Pharmaceuticals to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference >>

May 07, 2008

Hollis-Eden Pharmaceuticals Schedules First Quarter 2008 Conference Call and Webcast >>

April 14, 2008

Hollis-Eden Pharmaceuticals Presents Positive Data with APOPTONE(TM) in Preclinical Bone Model of Late-Stage Prostate Cancer >>

March 18, 2008

Hollis-Eden Pharmaceuticals Reports Positive Preliminary Data from Ongoing Phase I/II Clinical Trial with TRIOLEX(TM) in Obese Insulin Resistant Subjects >>

View All Releases >>

HIGHLIGHTS

2007 Annual Report

2007 Annual Report

2007 Annual ReportHollis-Eden’s 2007 Annual Report to Shareholders, available here, shares our passionate commitment to delivering breakthrough medicine and describes the progress we are making in developing a new class of small molecule compounds based on adrenal steroid hormones that play a fundamental role in human health. >>

Investor Conference Webcast

Investor Conference Webcast

Hollis-Eden presentation at the Rodman and Renshaw 5th Annual Global Healthcare Conference held May 20, 2008. Click here for webcast of presentation. >>